Introduction
============

Alzheimer's disease (AD) is the most common progressive age-related neurodegenerative disorder, characterized by debilitating effects on brain function, such as memory loss and decline in cognitive abilities ultimately resulting in loss of independent functioning ([@B105]; [@B5]; [@B106]). The two major pathological hallmarks of AD are extracellular amyloid plaques composed of insoluble amyloid beta (Aβ) protein, and intra-neuronal neurofibrillary tangles (NFTs) containing hyperphosphorylated tau ([@B61]; [@B58]; [@B96]; [@B79]; [@B19]). While a substantial body of evidence has implicated neuroinflammation, oxidative stress, excitotoxicity, and oligomeric Aβ toxicity as AD contributing factors, the precise mechanism of AD etiopathology remains unclear ([@B51]). Several studies have shown that dysregulated transition metal metabolism, particularly Cu, Fe, and Zn may be casually linked to the neuropathology of AD, and may enhance Aβ aggregation and toxicity ([@B23]; [@B24]; [@B42]).

Over the last two decades, several studies using clinical diagnosis and post-mortem AD brain tissue have shown that the levels of Cu, Fe, and Zn accumulate in large concentrations within Aβ plaques ([@B68]). Moreover, it has been demonstrated that Cu, Fe, and Zn are associated with the metabolism and functional roles of Aβ and amyloid precursor protein (APP; [@B99]). This has led to the hypothesis that abnormal biometal deposition may play an important role in the pathobiology of AD, and metal chelation may represent an important therapeutic strategy to prevent the onset or slow down the progression of AD ([@B23]; [@B40]; [@B12]; [@B18]). Levels of Cu and Fe are upregulated in the brain with age, suggesting that an age-dependent increase in bioactive transition metals may contribute to AD pathology ([@B75]). However, the anatomical distribution of these metals within the brain remains unclear. The latter is important for further etiological exploration and the development of agents for the treatment and management of AD.

Apart from the involvement of Cu and Fe, Zn may also play a critical role in the pathogenesis of AD, although the exact mechanism remains unclear ([@B45]; [@B52]; [@B76]; [@B93]; [@B122]). The transcription of APP is mediated by Zn-dependent transcription factors, Sp1 and NF-κB ([@B13]). Zn has also been shown to facilitate the oligomerization of Aβ ([@B102]). Furthermore, cleavage of APP by the protease α-secretase is inhibited by Zn ([@B86]). Therefore, it is highly likely that dysregulation of Zn may be involved in AD ([@B115]). The levels of Zn in brain tissue are modulated by two main families of Zn transporters; ZnTs (zinc transporters) and ZIPs (Zrt/Irt-like protein, SLC39). Briefly, the intracellular uptake of Zn by neurons is mediated by ZIP protein, and through activated Ca^2+^ voltage gated ion channels, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, and *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptors ([@B97]). The export of zinc extracellularly, or from the cytosol to the lumen of intracellular organelles is mediated by ZnTs. Although several Zn transporters have previously been investigated in several AD models, a more comprehensive study is warranted ([@B97]), especially in natural models which are likely more representative of late onset AD.

Several *in vitro* and *in vivo* models have been developed, the most commonly used being transgenic mice models ([@B16]). However, due to the high complexity of AD pathology, transgenic mice models recapitulate many, but not all, of the major features of AD, and their validity for the sporadic form of AD is questionable ([@B16]). In this context, the establishment and validation of a wild-type "natural" animal model of AD, which recapitulates the neuronal, neuropathological, and behavioral abnormalities of sporadic or late-onset AD, and is small and easy to handle, would be of great benefit.

Previous studies from our laboratory have identified the *Octodon degus*, a South American rodent endemic to Central Chile, as a "natural" rodent model for AD ([@B56]). The *O. degus* is a diurnal, visual, and highly social rodent that "naturally" develops several symptoms that can be linked to the neuropathology of AD. This caviomorph rodent lives up to an average of 7 years in captivity, making it an interesting model for use in longitudinal studies, including those related to the neurobiology of AD ([@B29]; [@B109]). The amino acid sequence of wild-type *O. degus* Aβ shares a high degree (97.5%) of genetic homology with humans ([@B56]; [@B16]). It was recently reported that age-relate changes in Aβ oligomers and *tau* phosphorylation in *O. degus* correlated with a decrease in both spatial and object recognition memory, and impaired postsynaptic and neural plasticity ([@B2]). However, changes in the levels and spatial distribution of Cu, Zn, and Fe, and other redox-active metals in the aged *O. degus* brain tissue are of particular interest.

In this study, we aim to further examine the homology between Alzheimer-type pathology in the South American rodent *O. degus* and sporadic AD in humans by studying the neuropathological abnormalities in the animal to determine if it is indeed a unique "natural" model for the study of the pathobiology of AD. We hypothesized that: (1) *O. degus* develop neuropathological abnormalities in the distribution of redox active biometals, such as Fe, Ca, Zn, Cu, and Al; (2) lysosomal markers are affected in the "natural" model, similar to human AD; (3) altered biometal trafficking pathways, including major Fe/Cu regulatory genes, selected ZnTs, and ZIPs may represent a potential mechanism for altered distribution of these biometals in brain sections across the entire life-cycle of the *O. degus*. To address these hypotheses, we quantitatively imaged the anatomical distribution of Cu, Fe, Zn, Ca, and Al, in the brains of aged *O. degus* by a laser ablation inductively coupled plasma (ICP) system using mass spectrometry (LA-ICPMS). We have delineated regions of interest (ROIs) and determined the biometal concentrations in the *O. degus* brain with advanced age. Using western blotting, we also investigated potential mechanisms for these changes by examining the expression of biometal trafficking pathways, including lysosomal function, major Fe/Cu regulatory genes, and selected ZnTs and ZIPs.

Materials and Methods {#s1}
=====================

Animals
-------

*Octodon degus* were obtained from a breeding colony at the animal facility of the University of Valparaiso and maintained in a controlled temperature room (23 ± 1°C), under a 12:12 h light/dark cycle, with water and food provided *ad libitum.* At the time of this study, 16 male *O. degus* were grouped by age, from 12 to 36 months of age (*n* = 8 per group). Ages were selected to represent the development of AD-like pathology (36 months). All efforts were made to minimize animal discomfort and stress while also limiting the number of animals used. Aged animals were anesthetized with Equitesin (2.5 ml/kg, i.p.) and injected with heparin (4 USP/kg, i.p.). Afterward, brains were surgically removed from their skulls and frozen in isopentane at -78.5°C. All procedures were conducted according to animal protocols approved by the Institutional Animal Care and Use Committee at the University of Valparaiso and Pontifical Catholic University of Chile.

Sample Preparation for LA-ICPMS
-------------------------------

Cryosections of brains of 10 μm thickness were mounted on silanized slides. Neighboring sections were stained with hematoxylin and eosin staining.

LA-ICPMS Instrumentation
------------------------

LA-ICPMS was performed using a NewWave NWR213 (New Wave UP 266, New Wave, Fremont, CA, USA) laser ablation pulsed laser sampling accessory connected to a PerkinElmer Nexion ICPMS. The material was ablated using a focused Nd:YAG laser and then transported by argon as carrier gas into the ICP plume. Following ion formation in the ICP ion source, the positively charged ions were extracted from the argon plasma (at ≈100 kPa) via the differentially pumped interface (at ≈130 Pa) between the sampler and skimmer cones into the high vacuum of the quadrupole mass analyzer, and were separated with respect to their mass-to-charge ratios and detected by the ion detector. The experimental parameters of LA-ICPMS were optimized with respect to the maximum ion intensity of ^63^Cu^+^ using a well-homogenized synthetic laboratory standard. Tissue was ablated using a laser setting of 25% of maximum power, with a repetition rate of 20 Hz, a laser spot size of 50 μm, and a scan speed of 25. The gas flows in the LA-sample chamber were 0.85 l/m for He, and 0.65 l/m for Ar. Elemental analysis on the ICPMS was performed using peak hopping scan mode, with a dwell time of 90.7 ms per amu, and an integration time of 24,048 ms. All mass spectrometric measurements were performed with established protocols in routine mode in Becker's BrainMet Laboratory (BrainMet--Bioimaging of Metals in Brain and Metallomics) at Forschungszentrum Jülich. Optimized experimental parameters have been previously described ([@B74]). Instrument response was calibrated using the NIST 614 and NIST 612 standards to produce images of the change in elemental distribution across the tissue. Image data was processed and calibrated using the IOLITE software, then rendered as color images using MATLAB.

Hematoxylin and Eosin Staining
------------------------------

Slides were over-stained with hematoxylin for 10 min and excess stain was removed by running under tap water for 2 min. Afterward, they were differentiated and destained by submerging in acid alcohol for a few seconds until sections appeared red then rinsed briefly under tap water to remove acid. Slides were blued in bicarbonate until nuclei stood out significantly then rinsed under tap water for 5 min. Afterward, the slides were submerged in 70% ethanol for 3 min, and then in eosin for 2 min. The slides were then taken through three changes of 95% ethanol, for 5 min each. Finally, slides were rinsed in 100% ethanol, coverslipped and mounted.

Western Blotting
----------------

*Octodon degus* brains were dissected on ice and immediately processed. Briefly, cortical tissue was homogenized in radioimmunoprecipitation assay buffer (RIPA buffer) \[50 mM, Tris--Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 1% sodium dodecyl sulfate (SDS)\], supplemented with a protease inhibitor cocktail (Sigma-Aldrich P8340) and phosphatase inhibitors (50 mM NaF, 1 mM Na~3~VO~4~, and 30 μM Na~4~P~2~0~7~), using a Potter homogenizer and then passed sequentially through different caliber syringes. Protein samples were centrifuged at 14,000 rpm at 4°C twice for 15 min. Total protein concentration was determined using the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA). Hippocampal samples (20 μg) were resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane The incubation with a primary antibody; then a secondary anti-goat peroxidase conjugated antibody (Pierce) was used and developed using an ECL kit (Western Lightning Plus ECL, PerkinElmer) following the manufacturer's instructions.

Statistical Analysis
--------------------

To validate the metal ion images (**Figure [1](#F1){ref-type="fig"}**) and quantify the levels of Cu, Fe, Zn, Ca, and Al in the hippocampus (**Figure [2](#F2){ref-type="fig"}**) and cortex (**Figure [3](#F3){ref-type="fig"}**) of *O. degus* with age, two-dimensional images were first acquired as previously described by [@B31]. The raw data that was collected from the IOLITE software were exported as Microsoft Excel files, and each line that was formed by ablation was exported to a different worksheet. A total of 60 lines were required for mapping the entire slide surface. Therefore, 60 IOLITE files were generated, and each one was exported to a new worksheet, culminating in 60 Excel worksheets. Each worksheet contained the results of the analyte values on the entire slide surface. Blanks were added to account for the argon atmosphere where there was no ablation, and the blank signal was subtracted from the sample signal. The results were normalized using ^13^C as an internal standard. The average net ^13^C ion intensity was used as a surrogate of slice thickness, and calculated from histograms of pixel values ([@B7]). Afterward, excel files were converted into a text file to generate an image using MATLAB. The MATLAB image was generated using (*x*, *y*) coordinates. The *x* data set were collected from the LA-ICPMS, and the *y* data set was based on the number of lines. The *z* value representing the relative intensity at each point was correlated with the *x* and *y* matrix plane. For the *x*-axis, the ICP-MS acquisition time was considered, and LA system scan speed were used. For the *y*-axis, the spacing among the lines was used. Finally, data were converted into a matrix plane (*x*, *y*) in MATLAB. For data acquisition, a transpose function (*w* = *z*′) was used to adjust the image, and maintain relative intensity at each point. MATLAB images were saved as 8 bit grayscale TIFFs and were corrected for linear drift (factor of 1 was used at the end of the sample next to the standard, and the correction factor progressively increased or decreased line by line toward the other end) using IMAGENA ([@B84]). The hippocampus and cortex, including glass background and entire section trace metal concentrations were calculated from ion intensities averaged from freely drawn ROIs (representing the location of the hippocampus and cortex, respectively) within ion intensity images using PMOD version 3.0^[1](#fn01){ref-type="fn"}^. This was repeated four times per sample to ensure greater reliability and accuracy of data. Microphotographs obtained prior to ablation and the RB4 Watson Paxinos Atlas^[2](#fn02){ref-type="fn"}^ were used to neuroanatomically define ROIs. Standard measurements were processed using Microsoft Excel algorithm calculating slope of the calibration curve. Data were analyzed based on concentration = (maximum counts - minimum counts) × (ion intensity-background)/(255 × slope). Results were expressed as mean ± standard error over the 5 vs 4 individual averages of regional element concentrations using Prism software (GraphPad Software Inc.). The classical Bonferroni threshold for 4 regions × 5 elements was *p* = 0.008. For the Holmes modified Bonferroni correction, a *p*-value of ≤0.05 was considered to be statistically significant for the first region, for the second 0.05/2, for the third 0.05/3 and so on.

![**LA-ICPMS imaging of Cu, Fe, Zn, Ca, and Al, in whole brain, sagittal sections of *O. degus* with age.** H&E stained histological sections are shown on the far left, and neighboring brain sections were used for LA-ICPMS of each of five metals.](fnagi-09-00066-g001){#F1}

![**(A)** Quantitative alteration of Cu, Fe, Zn, Ca, and Al in the hippocampus of *O. degus* with age. Significant difference between 1- and 3-year-old *O. degus*. ^∗^*p* \< 0.05. **(B)** Table of absolute values mean ± SEM.](fnagi-09-00066-g002){#F2}

![**(A)** Quantitative alteration of Cu, Fe, Zn, Ca, and Al in the frontal cortex of *O. degus* with age. Significant difference between 1- and 3-year-old *O. degus*. ^∗^*p* \< 0.05. **(B)** Table of absolute values mean ± SEM.](fnagi-09-00066-g003){#F3}

Western blots (**Figures [4](#F4){ref-type="fig"}**--**[7](#F7){ref-type="fig"}**), were quantified using ImageJ 1.47v (NIH; Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, MD, USA^[3](#fn03){ref-type="fn"}^, 1997--2010). Statistical analysis was performed using Prism software (GraphPad Software Inc.). Data were analyzed using the Student's *t*-test, and the *post hoc* Tukey's multiple comparison test was applied. A *p*-value of ≤0.05 was considered to be statistically significant.

![**Evidence for lysosomal aberrations in the frontal cortex with age.** **(A)** Altered levels of cathepsin D, V-ATPase, Aβ42, ATP13a2 were observed in the brain at 3 years of age compared to 1-year-old *O. degus*. The blots shown are representative data from an experiment repeated eight times. **(B)** Graphs are mean ± SEM brains from brains of eight *O. degus* for each age group. Significantly different ^∗^*p* \< 0.01 compared to 1-year-old *O. degus*. **(C)** Table of absolute values mean ± SEM.](fnagi-09-00066-g004){#F4}

![**Alterations in the expression of Cu/Fe metabolic protein in the frontal cortex with age.** **(A)** Altered levels of IRP2, DMT1, ALAS2, and FOS were reported in the brain at 3 years of age compared to 1-year-old *O. degus*. The blots shown are representative data from an experiment repeated eight times. **(B)** Graphs are mean ± SEM brains from brains of eight *O. degus* for each age group. Significantly different in 3-year-old ^∗^*p* \< 0.01 compared to 1-year-old *O. degus*. **(C)** Table of absolute values mean ± SEM.](fnagi-09-00066-g005){#F5}

![**Changes in the expression of ZIP protein in the frontal cortex with age.** **(A)** Altered levels of ZIP7,8 and ZIP14 were reported in the brain after 3 years of age compared to 1-year-old *O. degus*. The blots shown are representative data from an experiment repeated eight times. **(B)** Graphs are mean ± SEM brains from brains of eight *O. degus* for each age group. Significantly different in 3-year-old ^∗^*p* \< 0.01 compared to 1-year-old *O. degus*. **(C)** Table of absolute values mean ± SEM.](fnagi-09-00066-g006){#F6}

![**Changes in the expression of ZnT protein in the frontal cortex with age.** **(A)** Altered levels of ZnT1,3,4,6,7, and 10 were reported in the brain after 3-years of age compared to 1-year-old *O. degus*. The blots shown are representative data from an experiment repeated eight times. **(B)** Graphs are mean ± SEM for brains of eight *O. degus* for each age group. Significance ^∗^*p* \< 0.01 compared to 1-year-old *O. degus*. **(C)** Table of absolute values mean ± SEM.](fnagi-09-00066-g007){#F7}

Results
=======

Microdistribution of Cu, Fe, Zn, Ca, and Al, in Whole Brain Sections of *O. degus* as a Natural Model of Aging and AD Progression
---------------------------------------------------------------------------------------------------------------------------------

Biometal accumulation can only be examined in humans using post-mortem brain sections collected at the end stage of the disease, and the distribution of redox-active brain-metals during the pathobiology of AD remains unclear. By using the *O. degus*---a natural model for AD---dyshomeostasis in Cu, Fe, Zn, Ca, and Al distribution can be examined in various brain regions with age (from 1 to 3 years old) and AD progression (from early stage to late stage). Brain section elemental images are presented in **Figure [1](#F1){ref-type="fig"}**. These images were used for metals quantification in the brain regions of hippocampus and cortex (**Figures [2](#F2){ref-type="fig"}**, **[3](#F3){ref-type="fig"}**).

Several studies have shown that Cu is highly abundant in plaques but is present at lower than the limits of detection, in the whole brain of AD ([@B21]; [@B23]; [@B41]). Our Cu images in **Figure [1](#F1){ref-type="fig"}** show that the amount of Cu in the brain of *O. degus* increases with age. These increases are focused in the hippocampal and cortical regions of *O. degus*. **Figure [2](#F2){ref-type="fig"}** shows that Cu in the hippocampus of *O. degus* significantly increased with age, from 10.1 μg g^-1^ at 1 year of age to 52.1 μg g^-1^ at 3 years of age. Comparatively, an increase in the Cu level (21--65 μg g^-1^) was found in cortex from 1 to 3 years of age. Our imaging data suggests that Cu is enriched in the aging brain, and to a greater extent in the AD brain.

Similarly, Fe levels are increased with age in the brain of *O. degus*, indicating that, like Cu, Fe is an age-dependent enriched element in the brain (**Figure [1](#F1){ref-type="fig"}**). Fe was found to be increased in the hippocampus and cortex. The content of Fe in the hippocampus of 3 years old *O. degus* was in the range of 15--25 μg g^-1^, which was significantly higher than young *O. degus* (10--15 μg g^-1^). **Figure [3](#F3){ref-type="fig"}** also shows an obvious Fe increase in the cortex of *O. degus* with age. The Fe content in the cortex of 3-year-old *O. degus* was about 90--100 μg g^-1^, which was considerably higher than that of the 1-year-old *O. degus* (10--15 μg g^-1^).

The dysregulation of Zn in AD pathology is also of major interest ([@B115]). Our quantitative images of Zn in this study show the cortex and hippocampus are Zn-rich regions in brain **Figure [1](#F1){ref-type="fig"}**. The average content of Zn in the hippocampus was 10--15 μg g^-1^ and did not significantly increase with age. However, in the cortex, the content of Zn increased significantly with age, from ∼10 μg g^-1^ in 1-year-old *O. degus*, to ∼80 μg g^-1^ in 3-year-old *O. degus* (**Figures [1](#F1){ref-type="fig"}**, **[2](#F2){ref-type="fig"}**).

Ca represents another important metal that plays a fundamental role in normal brain cell function ([@B27]). The level of Ca was found to increase with age throughout the brain (**Figure [1](#F1){ref-type="fig"}**), and in the hippocampus and cortex in particular, supporting the hypothesis of the imbalance of calcium homeostasis and disturbed Ca flux in brain components in the development of AD.

A link between Al and AD has also been the subject of scientific debate for several decades ([@B1]; [@B33]). No significant increase in the levels of Al was observed in the hippocampus in our study. However, Al levels increased significantly in the cortex of aged *O. degus*, from ∼20 μg g^-1^ in 1-year-old *O. degus*, to ∼40 μg g^-1^ in 3-year-old *O. degus*.

Impaired Lysosomal Function in *O. degus*
-----------------------------------------

Lysosomal dysfunction, has previously been reported in AD and several transgenic rodent models ([@B3]; [@B28]; [@B119]). In frontal cortex, we found an age-dependent increase in cathepsin D activity from 1 to 3 years of age (**Figure [4](#F4){ref-type="fig"}**). An age-dependent reduction of subunit B2 of V-ATPase was also observed in the frontal cortex, the site of neuropathological changes in AD, suggestive of lysosomal impairment. We also examined the levels of Aβ peptide Aβ42, and the metal transporter, ATP13a2. Significantly increased concentrations of Aβ42, and decreased ATP13a2 levels were also observed after onset of neurological disease (**Figure [4](#F4){ref-type="fig"}**), providing further support for a relationship between AD and lysosomal aberrations.

IRP2, DMT1, ALAS2, and FOS expression in *O. degus*
---------------------------------------------------

To evaluate the biological significance of increased Cu and Fe with age, we measured the protein expression of IRP2 and DMT1 in the frontal cortex. DMT1 is a major transporter of divalent metal species and exists in two isoforms---one that contains an iron responsive element in the untranslated region and would be expected to be regulated by IRP2 (DMT1-IRE) and a second that lacks an IRE and should be regulated independently of IRP2 levels (DMT1-non-IRE) ([@B116]). We found a significant increase in expression of DMT1-non-IRE in 3-year-old *O. degus* compared to 1-year-old *O. degus* (**Figure [5](#F5){ref-type="fig"}**). However, IRP2 protein expression remained unchanged (**Figure [5](#F5){ref-type="fig"}**).

We also assessed the expression of additional proteins related to Cu and Fe metabolism. The proteins of interest were proto-oncogene c-Fos (FOS), and 5-aminolevulinate synthase (ALAS2) (**Figure [5](#F5){ref-type="fig"}**). We found a significant increase in expression of FOS in 3-year-old *O. degus* compared to 1-year-old *O. degus* (**Figure [5](#F5){ref-type="fig"}**). However, the levels of ALAS2 significantly declined with age in 3-year-old *O. degus* compared to 1-year-old *O. degus* (**Figure [5](#F5){ref-type="fig"}**). This suggests that alterations in the ratio of Cu and Fe significantly alter intracellular Cu/Fe pathways.

Age-Specific Alterations to Zn Transport Pathways
-------------------------------------------------

Western blotting revealed age related changes in the protein expression of Zip and ZnT metal transporter proteins. The expression of the ER/Golgi-resident transporter, Zip7, significantly reduced in the frontal cortex in an age-dependent manner in 3-year-old *O. degus*. Similarly, significantly reduced expression of Zip8, and Zip14 were observed in 3-year-old *O. degus* (**Figure [6](#F6){ref-type="fig"}**). On the contrary, the protein expression of ZnT1, ZnT3, ZnT4, ZnT6, and ZnT7 were significantly increased with age in the frontal cortex of 3-year-old *O. degus* (**Figure [7](#F7){ref-type="fig"}**). However, the expression of ZnT10 was significantly reduced. Therefore, dysregulated expression of ZIP and ZnT family may be associated with the progression and neuropathology of AD.

Discussion
==========

Natural animal models which closely resemble the etiopathogenesis of AD are needed for research on disease mechanisms and for drug development. No reliable "natural" model of AD is available, and current AD research largely uses transgenic models, which have a number of limitations, including the fact that they do not recapitulate the morphological and temporal patterns observed in clinical AD in humans ([@B16], [@B17]). Therefore, data on molecular mechanisms and drug efficacy testing using these genetically modified models should be interpreted with care, as many previous discoveries made in transgenic models have been lost in human translation ([@B16], [@B17]). Spontaneous age-related neurodegeneration reported in *O. degus* mimics many of the cellular and molecular events that have been observed extensively in experimental models and clinical AD ([@B56], [@B57]; [@B38]). An interesting feature of the AD-like changes observed in *O. degus* brains is the fact that they occur in aged animals and so far, have never been detected in young animals (1-year-old; [@B57]). In one study, 3-year-old wild-type *O. degus* have been shown to develop significant Aβ peptide deposition in blood vessel walls of the brain ([@B110]). Capillary Aβ deposition in the cerebral cortex has been recently reported in a population-based study of 601 individuals aged greater than 85 years, and was associated with the severity of dementia and AD-type pathology ([@B71]). Moreover, hippocampal tau deposits were shown to occur parallel to loss of myelin, indicative of significant white matter degeneration in that same study ([@B110]). Hippocampal tau deposits have also been detected in post-mortem AD brain tissue using THK5117, a radiotracer for positron emission tomography (PET) scan imaging of tau deposits ([@B65]). Moreover, white matter abnormalities have been shown to not only represent an early pathological event in AD, but may also be involved in Aβ aggregation and tau hyperphosphorylation ([@B95]). Taken together, we can postulate that amyloid and tau deposition are age-dependent processes in *O. degus*, as also occurs in clinical AD patients.

Abnormal metal deposition have also been reported in the APP/V717I transgenic mouse model and wild-type age-matched mice as controls using LA-ICPMS ([@B113]). However, very few studies using LA-ICPMS as a tool for biometal analysis, have been performed in the brain of "physiologically" aged rodent models. One study performed demonstrated a significant increase in Fe levels in the substantia nigra, the thalamus, and the CA1 region of the hippocampus of 14-month-old mice compared to 2-month-old mice ([@B8]). As iron is well known to form free radicals due to its high redox active properties, increased cerebral Fe levels may potentiate neurodegeneration. The same study showed that the levels of Zn remained unchanged with age. The latter supports the essential role of Zn as a major neurotransmitter that can be stored in vesicules. Another study showed that the global cerebral content of Cu was increased in 14-month-old mice compared to 2-month-old mice. However, reduced Cu uptake was noted in the striatum and ventral cortex in aged mice, which were associated with the highest decline in cerebral superoxide dismutase-1 (SOD-1). This further suggests that dysregulated Cu homeostasis may contribute to oxidative stress and neurodegeneration in the aging brain ([@B114]).

However, the current study is the first to identify specific age-related changes in biometal trafficking and transition metal distribution in *O. degus*, a potential "natural" model for AD. It is well established that deposition of the redox elements Fe and Cu contribute to Aβ-induced toxicity in the AD brain ([@B68]; [@B23]; [@B24]; [@B74]). Evidence shows the redox cycling of Cu contributes to the oxidative stress of AD ([@B21]; [@B27]; [@B52]; [@B76]). Although evidence for altered Cu levels in serum are conflicting, Cu has been found to be significantly dysregulated in patients with mild cognitive impairment (MCI) who subsequently progressed to dementia ([@B81]). Furthermore, the levels of Cu have been shown to be increased with age in the hippocampus and cortex of APP/V717I transgenic mice ([@B113]). Moreover, the ratio of Cu/Fe as well as Cu levels may be a useful biomarker to distinguish between progressive and cognitively stable MCI patients ([@B81]). This ratio is consistent with a previous study which examined the ratio of ceruloplasmin and transferrin (the major protein carriers of Cu and Fe, respectively) in serum from early AD cases: ceruloplasmin was increased while transferrin was decreased ([@B101]). However, an earlier study supported an increase in serum ceruloplasmin, but challenged the decrease in serum transferrin in AD ([@B80]).

We also observed a significant increase in the levels of Fe in aged *O. degus*. This is in line with previous findings in the APP/V717I transgenic mouse model, and age-matched mice as controls using LA-ICPMS ([@B113]), suggesting that Fe is age-dependently enriched in the brain. The increased Fe level is likely due to the constant transportation of Fe to the brain mediated by capillary endothelial cells, and increased release of Fe into the blood *via* the blood--brain barrier ([@B21]; [@B20]). While Fe was found mainly enriched in the substantia nigra and corpus callosum of APP mice ([@B113]), Fe was primarily found in the substantia nigra and cortical area of age-matched controls. However, several studies have shown that Fe is enriched in plaques, and the hippocampus and frontal cortex are the main plaque deposition regions ([@B21]; [@B66]). Therefore, increased Fe content in the hippocampal and cortical areas of the *O. degus* is suggestive of defective metal transport in some micro-regions of the AD brain. Quantitative results from a previous study using LA-ICPMS show an increased tendency for Fe in the hippocampi of both APP and age-matched controls, suggesting regional variations in Fe reactions in the brain ([@B113]). The increased level of Fe in the brain can be attributed to the presence of iron-binding proteins. Ferritin and transferrin, represent the two-most important Fe carriers, and are commonly found in both the white and gray matter ([@B22]; [@B107]). Therefore, accumulation of Fe may be due to the functional role of ferritin in the brain of *O. degus*. Additionally, serum levels of Fe in AD patients are inconsistent, and no study has specifically evaluated the levels of non-heme (chelatable) iron ([@B81]).

As well, Zn is an important redox-active metal that plays an important role in Aβ aggregation and extracellular plaque formation ([@B115]). Therefore, determining the mechanism(s) of Zn dysregulation in AD and aging is of particular interest. The microdistribution of zinc in aged *O. degus* is remarkably similar to a previous study in the APP/V717I transgenic mouse model ([@B113]). We observed a significant age-related increase in Zn levels in the cortex and hippocampus, which present as Zn-enriched regions.

Additionally, Ca represents another important metal that plays an important role in normal brain cell function ([@B67]). It is well established that increased Aβ can reduce the membrane potential, thus enhancing Ca^2+^ influx, leading to an accumulation of Ca^2+^ in cells, leading to excitotoxicity and cell death via apoptotic processes ([@B46]; [@B53]; [@B6]; [@B55]; [@B108]; [@B63]). Increased oxidative stress may further interfere with Ca immobilization, leading to cell death via additional cytotoxic pathways ([@B39]; [@B83]). It has been previously reported that Ca^2+^ overload can modulate APP metabolism, and accelerate APP hydrolysis to generate more Aβ ([@B112]; [@B120]). Our study and others have shown that Ca increases with age in the brain, and provides further evidence supporting the hypothesis of the imbalance of calcium homeostasis and disturbed Ca flux in the brain can enhance AD progression ([@B89], [@B90]; [@B34]; [@B73]; [@B60]; [@B82]; [@B4]).

Numerous studies have shown that Al may also contribute to the pathology of AD ([@B72]; [@B30]; [@B37]; [@B64]; [@B94]; [@B103]). A collective body of published work indicates that: (1) Al accumulates in microtubules and induces cortical atrophy *in vivo* ([@B44]), (2) Al may be involved in the formation of extracellular plaques and NFTs ([@B78]; [@B77]; [@B88]); (3) Increased incidence of AD has been observed in populations where there are high levels of Al in drinking water supplies ([@B43]; [@B72]; [@B54]; [@B91]; [@B49]; [@B88]); (4) Al chelators have shown positive responses for the treatment of AD in transgenic rodent models ([@B50]; [@B59]); and (5) Increased Al deposition is also associated with the pathogenesis of other neurodegenerative diseases including Parkinson's disease and amyotrophic lateral sclerosis ([@B11]; [@B98]). While our study shows that Al is increased with age in the cortex, no other study has reported changes in Al distribution in the brain in other AD models, and it is still unclear whether Al levels are elevated in human AD patients. Thus, further studies are warranted to elucidate the association between Al levels and AD.

The expression of cellular trafficking systems plays a critical role in metal-induced toxicity. Abnormalities in the lysosomal pathway have been previously reported in AD pathology, prior to the development of NFTs or Aβ plaques ([@B26]; [@B25]). Since proteolytic processing of APP is necessary for the formation of Aβ, lysosomal proteases have been linked with AD pathology ([@B111]). The increased expression of cathepsin D reported in this study may represent a compensatory mechanism to restore lysosomal function ([@B87]). This is supported by another study which showed that knockout of cathepsin D enhances abnormal tau phosphorylation, and oxidative stress in the brain ([@B62]). Cathepsin D also has an important role of maintaining neuronal homeostasis, and optimal function of cathepsin D is therefore necessary for the clearance of unfolded/oxidized protein that are transported to lysosomes to facilitate their removal ([@B9]). Similarly, vesicular ATPases are required to acidify lysosomes and maintain an optimal acidic environment for lysosomes ([@B117]). One study showed that degradation or reduced expression of V-ATPase can enhance AD pathology by making neurons more susceptible to insult following exposure to pathological concentrations of Aβ and tau ([@B117]). Therefore, the observed changes in cathepsin D and V-ATPase may provide an additional mechanism for the failed protein degradation, abnormal accumulation of pathological hallmarks of AD, including Aβ (which was increased in this study), and age-related neurodegeneration.

Mutations, altered expression or aberrant functionality of several metal transporters belonging to the ATP7, ATP13, TRMPL, and ZnT families have also been implicated in neurodegenerative disorders ([@B69]; [@B70]; [@B92]; [@B121]). Increased ATP13a2 expression has previously been shown to attenuate lysosomal dysfunction in fibroblasts derived from PD patients ([@B35],[@B36]). Therefore, it is likely that downregulation of ATP13a2 in aged *O. degus* may impair lysosomal function. Neurodegenerative processes involving aberrant cellular metal trafficking may be intricately linked at the molecular level.

While Cu/Fe dysregulation may represent a useful biomarker for AD, on its own it is not conclusive. We analyzed the expression of several proteins, including: IRP2, a central regulator of intracellular iron and copper metabolism, and a downstream target of IRP2, the IRE-containing gene DMT1, FOS, and ALAS2 in the frontal cortex of *O. degus*. Alterations in the expression of regulatory proteins associated with the metabolism and transport of Cu and Fe suggest that homeostasis of these redox active metals is dysregulated in *O. degus*, and contributes to the age-related changes in the microdistribution of Cu and Fe ([@B81]).

In the brain, Zn is transported by several members of the ZIP and ZnT family of transporters. A significant reduction in members of the ZIP family of transporters was observed in our study. In particular, our results are the first to show an age-related decline in the expression of ZIP7,8 and 14 in the brain of aged *O. degus*. It is likely that the loss of ZIP expression may stimulate perturbations in the metabolism of other redox-active metals ([@B32]; [@B47],[@B48]). Excess unbound Zn may displace other redox-active transition metals from metalloproteins, and further promote formation of highly volatile free-radicals via Fenton chemistry ([@B118]). Increased free Zn may also inhibit protein tyrosine phosphatases in the endoplasmic reticulum, inhibiting the propagation of "Zn wave" signals throughout cells, thus impairing pleiotropic cellular signaling processes important for cellular survival ([@B104]).

Previous studies have reported upregulation of ZnT1, ZnT3, ZnT4, ZnT5, ZnT6, and ZnT7 protein isoforms in the hippocampus and neocortex in APP/PS1 mice ([@B69]; [@B100]; [@B123]). Similarly, we have shown that ZnT1, ZnT3, ZnT4, ZnT6, and ZnT7 are increased with age. On the other hand, a previous study showing that ZnT3 mRNA and protein levels are reduced in the human AD brain ([@B10]). Two earlier studies have shown that ZnT1 is decreased significantly in the hippocampus of subjects with MCI (a stage from which 30% progress to develop dementia) and pre-clinical AD (PCAD; where subjects have no overt clinical manifestations of AD but pathology is revealed post-mortem) ([@B69]), as well as in AD. Moreover, while ZnT4 and ZnT6 were elevated in PCAD and in the hippocampus of AD patients, no significant difference in levels was reported for either transporter between MCI and age-matched controls ([@B70]). ZnT3 is the main Zn transport protein and a major contributor to Zn^2+^ release from the synaptic cleft to Zn-enriched terminals, and may also be responsible for the abnormal distribution of Zn in the brain ([@B85]). Under normal physiological conditions, the levels of unbound Zn are regulated by metallothionein, and the endogenous antioxidant enzyme, SOD. However, under pathological conditions, Zn may remain unbound over a significant length of time, and may therefore interact with Aβ and enhance plaque deposition ([@B15]).

Little information is known about the functional role of Zn10 in AD. A recent study has shown that ZnT10 expression is upregulated in post-mortem AD brain tissue ([@B14]). By contrast, our results show that ZnT10 expression is reduced in the frontal cortex of aged *O. degus*. Under physiological conditions, ZnT10 is localized to the Golgi apparatus, and maybe translocated to the plasma membrane following an increase in Zn levels leading to a down-regulation of ZnT10 expression ([@B14]). Therefore, it is possible that the increase in Zn may reduce ZnT10 expression early in disease course as reported in this study. Reduced expression of ZnT10 may exacerbate AD progression effluxing Zn into the extracellular space, and providing Zn ions to facilitate Aβ deposition and senile plaque formation.

Our current study has utilized LA-ICPMS and neuro-molecular biology techniques to examine the microdistribution of redox-active transition metals, and biometal trafficking pathways in the brain of aging *O. degus*. Since age is the greatest risk factor for AD, our present findings provide a rationale for further utilization of the metallomic approach in research and drug development to extend lifespan and maintain healthspan.
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